Skip to content

Menu

About CLTI
Technology
- Products
Clinical Evidence
U.S. Clinical Trial
Company
- Management
- Clinical Advisors
- News
- Media
- Articles
- Careers
Contact
International

June 6 2017

Midterm Outcomes From a Pilot Study
of Percutaneous Deep Vein Arterialization
for the Treatment of No-Option
Critical Limb Ischemia

View the article.

LimFlow Expands Senior Management Team and Opens Silicon Valley Office LimFlow Announces First Patient Treated in U.S. Feasibility Study and Commencement of International Post-Market Study

Related Posts

LIMFLOW APPOINTS MIKE MATHIAS AS VICE PRESIDENT, COMMERCIAL OPERATIONS

LIMFLOW APPOINTS JENNY GAFFNEY AS VICE PRESIDENT, HEALTH ECONOMICS AND REIMBURSEMENT

LIMFLOW RAISES $40 MILLION (€36 MILLION) IN SERIES D FINANCING

Recent Posts

LIMFLOW APPOINTS MIKE MATHIAS AS VICE PRESIDENT, COMMERCIAL OPERATIONS
LIMFLOW APPOINTS JENNY GAFFNEY AS VICE PRESIDENT, HEALTH ECONOMICS AND REIMBURSEMENT
LIMFLOW RAISES $40 MILLION (€36 MILLION) IN SERIES D FINANCING
US PIVOTAL STUDY AND CLARITI COMPLETE ENROLLMENT
LATE-BREAKING DATA FROM PROMISE I STUDY ON LIMFLOW SYSTEM CONFIRM EXCELLENT SUSTAINED OUTCOMES IN PATIENTS WITH NO-OPTION CHRONIC LIMB-THREATENING ISCHEMIA

CAUTION: Investigational device. Limited by Federal law to investigational use.:

The LimFlow System is approved for sale in markets regulated by the CE Mark.

©2020-present LimFlow SA | Site designed by The Deciding Factor, Inc.